Neola Medical’s Neonatal Lung Monitor Clears Key Pilot Milestone

Neola Medical AB (SE:NEOLA) announced an update on their ongoing clinical study.

The clinical pilot study “Clinical Pilot Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates” evaluates Neola Medical AB’s new lung monitor in fragile preterm infants. The goal is to confirm basic safety and real world performance, which is a key step toward broader clinical use and potential commercial rollout.

The intervention is a noninvasive monitoring device called Neola®, designed to track lung function in newborns at risk of respiratory distress. It aims to give staff continuous bedside data so that breathing problems can be detected earlier and treatment can be adjusted more precisely.

The study is interventional with a single experimental group, where all enrolled neonates receive monitoring with Neola®. There is no randomization or blinding, and the main purpose is practical evaluation of safety and device performance rather than proof of superiority versus standard care.

The trial has an overall status of completed, signaling that patient enrollment and follow up are finished. The latest update was submitted on 16 March 2026, which suggests that data handling and analysis are active and that investors can expect more detailed results in the near term.

For investors, a completed pilot study reduces technical risk around Neola® and can support future regulatory filings and partnerships. Positive safety and performance data could strengthen market perception of Neola Medical AB versus other neonatal monitoring players and may act as a catalyst for stock sentiment as the company moves toward commercialization.

This study is now completed and recently updated, with further details available on the ClinicalTrials portal.